Ego Pharmaceuticals, a leading Australian dermatological skincare company is proudly celebrating two major milestones this year, with 70 years of operations globally and 30years in the Middle East.
Ego Pharmaceuticals became the first Australian skincare company to venture into the Middle East, despite being relatively unknown at the time. Over three decades, Ego has solidified its presence in the region, which currently contributes to 50% of its total exports and 25% of its overall global business.
With a workforce of 110 professionals across 7 Middle Eastern countries, Ego Pharmaceuticals is moving to a new MEA support centre in central Dubai this September and expanding operations in Saudi Arabia later in the year.
Alan Oppenheim, Managing Director, said of the company’s journey: “Ego’s entry into the Middle East was a significant leap for our small company. Looking back on the collective efforts of our teams in Australia and the Middle East over these three decades fills me with immense pride. Knowing that our products have played a role in improving the lives of those in the Middle East dealing with chronic skin conditions is truly gratifying. We are now a leading Australian company with sustainable operations in a vibrant and growing Middle East market.”
Ego Pharmaceuticals’ dedication to the Middle East has resulted in consistent growth. From its initial entry into the UAE in 1993, the company expanded its presence into Bahrain, Jordan, Saudi Arabia, Kuwait, Qatar, and Oman. Recognitions include awards at the Australian Export Awards for Health and Biotechnology in 2015, as well as the Manufacturing Export Award and Australian Exporter of the Year title in 2017.
Ego’s thriving export success to the Middle East has led to significant investments in its Australian operations, based in Melbourne, including current projects to upgrade to its manufacturing facility and the expansion of its global distribution centre. These initiatives are expected to increase production capacity by 100% and create 90 new jobs.
